• About
    • Who We Are
    • Leadership Team
    • Board of Directors
    • Clinical and Scientific Advisors
    • Contact
  • Science
    • Immune Continuum
    • CCR4 in Cancer
    • CCR4 in Inflammation
    • HPK1
    • Publications
  • Pipeline
    • Snapshot
    • FLX475
    • RPT193
    • HPK1
    • Discovery Programs
  • Investors & Media
    • Corporate Profile
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Email Alerts
    • Investor Contact
    • Investor FAQs
  • Careers
    • Culture
    • Benefits
    • Open Positions

PRESS RELEASES

Year
January 03 | 2023
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 08 | 2022
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
November 30 | 2022
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 17 | 2022
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
November 17 | 2022
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 10 | 2022
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
November 09 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
September 28 | 2022
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
August 31 | 2022
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 11 | 2022
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Contact Us
+1.650.489.9000
inquiries@rapt.com
  • Home
  • About
  • Science
  • Pipeline
  • Investors & Media
  • Careers
  • Terms Of Use
  • Privacy Policy

RAPT Therapeutics
561 Eccles Avenue
South San Francisco, CA 94080
Tel: +1 650 489 9000
Email: inquiries@rapt.com

RAPT Therapeutics, formerly known as FLX Bio.

© 2023 RAPT Therapeutics. All right reserved.